The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry

PURPOSE: The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rate and receptor subtype discordance rate in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Meegdes, Marissa, Ibragimova, Khava I. E., Lobbezoo, Dorien J. A., Vriens, Ingeborg J. H., Kooreman, Loes F. S., Erdkamp, Frans L. G., Dercksen, M. Wouter, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., Pepels, Manon J. A. E., van de Winkel, Linda M. H., Tol, Jolien, Heijns, Joan B., van de Wouw, Agnes J., Peters, Natascha A. J. B., Hochstenbach-Waelen, Ananda, Smidt, Marjolein L., Geurts, Sandra M. E., Tjan-Heijnen, Vivianne C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926963/
https://www.ncbi.nlm.nih.gov/pubmed/35025003
http://dx.doi.org/10.1007/s10549-021-06472-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926963/
https://www.ncbi.nlm.nih.gov/pubmed/35025003
http://dx.doi.org/10.1007/s10549-021-06472-5

Ejemplares similares